D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia

计划入组 52 人 · 首次发布于 2009 年 8 月 17 日

Diamine Oxidase and Adverse Pregnancy Outcomes

计划入组 75 人 · 首次发布于 2024 年 2 月 28 日

Xanthine Oxidase Inhibition in Renal Transplant Recipients

计划入组 20 人 · 首次发布于 2011 年 4 月 11 日

Lumasiran(Oxlumo)

Glucose oxidase

NADPH oxidase stimulators

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

RNA Interference Therapy Market Expands with 90+ Drugs in Development Across 40+ Companies

FDA Approves Alnylam's Oxlumo as First Treatment for Ultra-Rare Kidney Disease PH1

iVeena Delivery Systems Announces Successful Phase 1 Results for IVMED-85, a First-in-Class Lysyl Oxidase Activator for Pediatric Myopia